X4 (XFOR) falls 3.69% to Close at $2.17 on January 14

Equities Staff  |

X4 Pharmaceuticals Inc (NASDAQ: XFOR), a Lafayette, Indiana, company, fell to close at $2.17 Friday after losing $0.08 (3.69%) on volume of 205,352 shares. The stock ranged from a high of $2.20 to a low of $2.02 while X4’s market cap now stands at $51,639,873.

About X4 Pharmaceuticals Inc

X4 Pharmaceuticals is a late-stage clinical biopharmaceutical company and a leader in the discovery and development of novel therapies for the treatment of diseases resulting from dysfunction of the CXCR4 pathway, with a focus on rare diseases and those with limited treatment options. The company's lead candidate, mavorixafor, is a first-in-class, small molecule antagonist of chemokine receptor CXCR4 being developed as a once-daily oral therapy. X4 believes that inhibition of the CXCR4 receptor creates the potential for mavorixafor to provide therapeutic benefit across a wide variety of diseases, including primary immunodeficiencies and certain types of cancer. The efficacy and safety of mavorixafor, dosed once daily, is currently being evaluated in a global Phase 3 clinical trial in patients with WHIM syndrome, and in two Phase 1b clinical trials - in combination with ibrutinib in patients with Waldenstrom macroglobulinemia, and as monotherapy in patients with severe congenital neutropenia (SCN). X4 is continuing to leverage its insights into CXCR4 biology at its corporate headquarters in Boston, Massachusetts and at its research facility in Vienna, Austria, and is developing additional product candidates.

Visit X4 Pharmaceuticals Inc’s profile for more information.

About The Nasdaq Stock Market

The Nasdaq Stock Market is a global leader in trading data and services, and equities and options listing. Nasdaq is the world's leading exchange for options volume and is home to the five largest US companies - Apple, Microsoft, Amazon, Alphabet and Facebook.

To get more information on X4 Pharmaceuticals Inc and to follow the company’s latest updates, you can visit the company’s profile page here: X4 Pharmaceuticals Inc’s Profile. For more news on the financial markets be sure to visit Equities News. Also, don’t forget to sign-up for the Daily Fix to receive the best stories to your inbox 5 days a week.

Sources: Chart is provided by TradingView based on 15-minute-delayed prices. All other data is provided by IEX Cloud as of 8:05 pm ET on the day of publication.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer


Trending Articles

Kroger App Causes Customer Frustration, Hurts Brand: Jeff Kagan
The Shipping Container Was the Most Important Invention of the 20th Century
Currencies and the Global Expansion of Money Supply
Commodities Post Strongest Gains in Over a Decade



Market Movers

Sponsored Financial Content